vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and JFrog Ltd (FROG). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $145.3M, roughly 2.0× JFrog Ltd). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -10.5%, a 106.8% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs 9.4%). Over the past eight quarters, JFrog Ltd's revenue compounded faster (20.4% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
ACAD vs FROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $145.3M |
| Net Profit | $273.6M | $-15.2M |
| Gross Margin | 90.8% | 77.9% |
| Operating Margin | 6.1% | -14.7% |
| Net Margin | 96.3% | -10.5% |
| Revenue YoY | 9.4% | 25.2% |
| Net Profit YoY | 90.3% | 34.4% |
| EPS (diluted) | $1.61 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $145.3M | ||
| Q3 25 | $278.6M | $136.9M | ||
| Q2 25 | $264.6M | $127.2M | ||
| Q1 25 | $244.3M | $122.4M | ||
| Q4 24 | $259.6M | $116.1M | ||
| Q3 24 | $250.4M | $109.1M | ||
| Q2 24 | $242.0M | $103.0M | ||
| Q1 24 | $205.8M | $100.3M |
| Q4 25 | $273.6M | $-15.2M | ||
| Q3 25 | $71.8M | $-16.4M | ||
| Q2 25 | $26.7M | $-21.7M | ||
| Q1 25 | $19.0M | $-18.5M | ||
| Q4 24 | $143.7M | $-23.2M | ||
| Q3 24 | $32.8M | $-22.9M | ||
| Q2 24 | $33.4M | $-14.3M | ||
| Q1 24 | $16.6M | $-8.8M |
| Q4 25 | 90.8% | 77.9% | ||
| Q3 25 | 92.2% | 77.4% | ||
| Q2 25 | 92.2% | 76.3% | ||
| Q1 25 | 91.7% | 75.3% | ||
| Q4 24 | 91.6% | 75.4% | ||
| Q3 24 | 92.5% | 75.0% | ||
| Q2 24 | 92.5% | 78.8% | ||
| Q1 24 | 88.8% | 79.5% |
| Q4 25 | 6.1% | -14.7% | ||
| Q3 25 | 12.8% | -15.8% | ||
| Q2 25 | 12.2% | -20.4% | ||
| Q1 25 | 7.9% | -18.8% | ||
| Q4 24 | 59.1% | -21.9% | ||
| Q3 24 | 12.6% | -27.4% | ||
| Q2 24 | 12.6% | -18.6% | ||
| Q1 24 | 7.4% | -16.6% |
| Q4 25 | 96.3% | -10.5% | ||
| Q3 25 | 25.8% | -12.0% | ||
| Q2 25 | 10.1% | -17.0% | ||
| Q1 25 | 7.8% | -15.1% | ||
| Q4 24 | 55.4% | -20.0% | ||
| Q3 24 | 13.1% | -21.0% | ||
| Q2 24 | 13.8% | -13.9% | ||
| Q1 24 | 8.0% | -8.8% |
| Q4 25 | $1.61 | $-0.13 | ||
| Q3 25 | $0.42 | $-0.14 | ||
| Q2 25 | $0.16 | $-0.19 | ||
| Q1 25 | $0.11 | $-0.16 | ||
| Q4 24 | $0.86 | $-0.21 | ||
| Q3 24 | $0.20 | $-0.21 | ||
| Q2 24 | $0.20 | $-0.13 | ||
| Q1 24 | $0.10 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $704.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $887.4M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $704.4M | ||
| Q3 25 | $258.0M | $651.1M | ||
| Q2 25 | $253.6M | $611.7M | ||
| Q1 25 | $217.7M | $563.5M | ||
| Q4 24 | $319.6M | $522.0M | ||
| Q3 24 | $155.1M | $467.8M | ||
| Q2 24 | $177.1M | $591.3M | ||
| Q1 24 | $204.7M | $579.6M |
| Q4 25 | $1.2B | $887.4M | ||
| Q3 25 | $917.3M | $859.4M | ||
| Q2 25 | $822.4M | $826.5M | ||
| Q1 25 | $765.2M | $800.0M | ||
| Q4 24 | $732.8M | $773.5M | ||
| Q3 24 | $577.2M | $756.2M | ||
| Q2 24 | $516.7M | $721.4M | ||
| Q1 24 | $464.0M | $707.8M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $976.9M | $1.1B | ||
| Q2 24 | $914.1M | $1.0B | ||
| Q1 24 | $855.1M | $997.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $50.7M |
| Free Cash FlowOCF − Capex | — | $49.9M |
| FCF MarginFCF / Revenue | — | 34.3% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $142.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $50.7M | ||
| Q3 25 | $74.3M | $30.2M | ||
| Q2 25 | $64.0M | $36.1M | ||
| Q1 25 | $20.3M | $28.8M | ||
| Q4 24 | $40.4M | $49.1M | ||
| Q3 24 | $63.2M | $27.6M | ||
| Q2 24 | $25.0M | $16.7M | ||
| Q1 24 | $29.1M | $17.5M |
| Q4 25 | — | $49.9M | ||
| Q3 25 | $73.9M | $28.8M | ||
| Q2 25 | — | $35.5M | ||
| Q1 25 | — | $28.1M | ||
| Q4 24 | — | $48.5M | ||
| Q3 24 | $63.2M | $26.7M | ||
| Q2 24 | — | $16.0M | ||
| Q1 24 | — | $16.6M |
| Q4 25 | — | 34.3% | ||
| Q3 25 | 26.5% | 21.0% | ||
| Q2 25 | — | 27.9% | ||
| Q1 25 | — | 23.0% | ||
| Q4 24 | — | 41.8% | ||
| Q3 24 | 25.2% | 24.5% | ||
| Q2 24 | — | 15.5% | ||
| Q1 24 | — | 16.6% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.1% | 1.0% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
FROG
Segment breakdown not available.
